Alison Lin

Alison Lin is an experienced financial professional currently serving as the Director of FP&A at Scribe Therapeutics since September 2023, after previously holding the position of Associate Director of FP&A at Atreca, Inc. from September 2021 to September 2023. Alison's career includes roles such as Associate Director of FP&A at Five Prime Therapeutics, Inc., and Senior Manager FP&A at both Five Prime Therapeutics, Inc. and Allogene Therapeutics. Additional experience includes a senior managerial position at Achaogen and various financial analyst roles at Gilead Sciences and Bio-Rad Laboratories. Prior to transitioning into finance, Alison worked as an Audit Senior at Deloitte & Touche. Educational qualifications include an MBA from the University of California, Berkeley's Haas School of Business and a Bachelor's degree from the same institution.